SCA
JAZZ icon

Strategic Capital Alternatives’s Jazz Pharmaceuticals JAZZ Stock Holding History

Strategic Capital Alternatives’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-138
Closed -$24K – 388
2015
Q2 		$24K Hold
138
– – 0.01% 359
2015
Q1 		$24K Buy
+138
New +$23.7K 0.01% 267

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Strategic Capital Alternatives's JAZZ Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 138 shares — an estimated $24K sold.

Strategic Capital Alternatives first reported a position in JAZZ in Q1 2015 and held it in 2 quarters. The position peaked at $24K in Q2 2015. 362 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 138 Jazz Pharmaceuticals shares in Q3 2015, an estimated $24K.
  • Strategic Capital Alternatives first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Strategic Capital Alternatives's Jazz Pharmaceuticals position peaked at $24K in Q2 2015.
  • 362 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.